



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2014
(Rs in Lakhs except EPS & Share holding)

Part I		3 months Ended	3 months Ended	3 months Ended	Year Ended	Year Ended
Sl. No.	Particulars	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
1	Income from Operations :			711.06	3,395.21	2,806.73
	(a) Net Sales / Income from Operations	938.53	881.25	-	12.25	-
	(b) Other Operating Income	4.36	3.70	-	-	-
	Total Income From operations (net)	942.89	884.95	711.06	3,407.46	2,806.73
2	Expenses :			15.29	121.69	56.74
	a) Operating Expenses	37.97	33.26	602.96	2,760.83	2,345.64
	b) Purchases of stock in trade	757.46	715.95	0.36	(9.70)	0.21
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	(3.88)	(2.50)	8.82	47.40	32.47
	d) Employee benefits expense	13.86	12.05	19.65	114.25	71.70
	e) Depreciation and amortisation expense	32.47	30.25	11.24	50.00	44.10
	f) Power And Fuel	12.14	12.24	3.73	16.79	15.15
	g) Freight and Forwarding Expenses	4.81	4.78	22.67	85.30	80.98
	h) Other Expenses	22.74	20.95	684.72	3,186.56	2,646.99
	Total Expenses (a+b+c+d+e+f+g+h)	877.57	826.98	684.72	3,186.56	2,646.99
3	Profit/(Loss) from operations before other income and Finance costs (1-2)	65.32	57.97	26.34	220.90	159.74
4	Other Income- (Interest)	-	-	26.34	220.90	159.74
5	Profit/(Loss) from ordinary activities before finance Cost (3+4)	65.32	57.97	26.34	220.90	159.74
6	Finance cost	52.92	47.25	13.74	178.05	51.61
7	Profit/(Loss) from ordinary activities before Tax (5-6)	12.40	10.72	12.60	42.85	108.13
8	Tax expenses:			(35.32)	-	(35.32)
	(a) Current tax	-	-	9.33	8.97	39.33
	(c) Deferred tax	2.97	2.00	(25.99)	8.97	4.01
	Total (a-b+c)	2.97	2.00	38.59	33.88	104.13
9	Net profit/(Loss) for the period (7-8)	9.43	8.72	38.59	33.88	104.13
10	Minority intrest	-	-	-	-	-
11	Net Profit/(Loss) after Taxes and minority intrest (9-10)	9.43	8.72	38.59	33.88	104.13
12	Paid up Equity Share Capital (Face value of `10/- per share	724.38	724.38	724.38	724.38	724.38
13	Reserves excluding Revaluation Reserve as per balance she	-	-	-	537.68	503.81
14	Earnings Per Share(of `10/- each) (not annualised)					
	a) Basic	0.13	0.12	0.53	0.47	1.44
	b) diluted	0.13	0.12	0.53	0.47	1.44



Part II						
A Select Information for the Quarter ended 31st Mar, 2014						
Sl. No.	Particulars	3 months Ended	3 months Ended	3 months Ended	Year Ended	Year Ended
		31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
1	Public Shareholding					
	- Number of shares	4403250	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%	60.79%
2	Promoter and Promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	--	--	--	--	--
	-Percentage of shares to promoter group	--	--	--	--	--
	- Percentage of shares to total capital	--	--	--	--	--
	b) Non-Encumbered					
	- Number of Shares	2840500	2840500	2840500	2840500	2840500
	-Percentage of shares to promoter group	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares to total capital	39.21%	39.21%	39.21%	39.21%	39.21%
Particulars					3 Months ended 31/03/2014	
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter				NIL	NIL
	Received during the quarter				NIL	NIL
	Disposed of during the quarter				NIL	NIL
	Remaining unresolved at the end of the quarter				NIL	NIL
NOTES:						
1. The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 30.05.2014						
2. The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment.						
3. There were no complaints from investors outstanding at the beginning of the Quarter ended 31st March 2014 and the Company has not received any complaints during the quarter ended 31st March 2014						
4. Previous period / year figures have been regrouped wherever necessary.						
The figures of last quarter are the balancing figures between audited figures in respect to the full financial year upto March 31, 2014 and the unaudited published year to date figures upto December 31, 2013, being the date of the end of the third quarter of the financial year which were subject to limited review.						
Station: HYDERABAD						
Date : 30.05.2014						
For Concord Drugs Limited						
S. Nagi Reddy						
S. Nagi Reddy						
Managing director						

